论文部分内容阅读
目的研究他莫昔芬(TAM)对人肝癌HepG2细胞增殖的影响,探讨其作用机制。方法将他莫昔芬配制为0、7.5、l5、30μmol/L,与人肝癌HepG2细胞培养24、48、72h,用四甲基偶氮唑蓝(MTT)法测定人肝癌HepG2细胞的抑制率;免疫组化染色观察人肝癌HepG2细胞Smad7蛋白的阳性表达。结果人肝癌HepG2细胞增殖随他莫昔芬浓度增加和处理时间的延长,细胞抑制率明显增加,细胞浆内Smad7蛋白阳性表达率明显降低,与时间和浓度呈负相关。结论他莫昔芬可抑制肝癌细胞增殖,可能与下调Smad7蛋白的表达有关。
Objective To study the effect of tamoxifen (TAM) on the proliferation of human hepatoma HepG2 cells and to explore its mechanism. Methods Tamoxifen was formulated into HepG2 cells at 0, 7.5, 15 and 30μmol / L for 24,48 and 72 hours, respectively. The inhibitory rates of HepG2 cells were determined by MTT assay The positive expression of Smad7 in HepG2 cells was observed by immunohistochemistry. Results With the increase of tamoxifen concentration and prolongation of treatment time, the proliferation of HepG2 cells was significantly increased, and the positive rate of Smad7 protein in cytoplasm was significantly decreased, negatively correlated with the time and concentration. Conclusion Tamoxifen can inhibit the proliferation of hepatoma cells, which may be related to the down-regulation of Smad7 protein expression.